Fig. 1 · Structure

Documents & Downloads

Spliceostatin A

Cat. No. A12700 CAS 391611-36-2
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA.

This product is currently unavailable.

Ask us for lead time and price.

Inquire about this product

Publications for Spliceostatin A

8 publications citing this product

  1. Arfaoui A, .et al. , EMBO Mol Med, 2019, Oct;11(10):e9930 PMID: 31476112
  2. KE Mengwasser, .et al. , ‎Mol Cell, 2019, S1097-2765(18)31062-1 PMID: 30686591
  3. Sahar AlShareef, .et al. , BMC Genomics, 2017, 18: 260 PMID: 28347276
  4. Ling Y, .et al. , Plant J, 2017, Jan;89(2):291-309 PMID: 27664942
  5. Matthew J. Hangauer, .et al. , Nature, 2017, Nov 9; 551(7679): 247-250 PMID: 29088702
  6. Ji Hyun Kim, .et al. , Animal Cells and Systems, 2017, 21:1, 17-22 PMID: 30460047
  7. M Tanikawa, .et al. , Oncogenesis, 2016, Dec; 5(12): e280 PMID: 27991914
  8. Ji Hyun Kim, .et al. , Biochim Biophys Acta, 2016, Jun; 1863(6 Pt A): 1307-1318 PMID: 27033521

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Spliceostatin A perturbs SF3b-associated pre-mRNA recognition. In HeLa nuclear extracts, it inhibited splicing and reduced SF3b155–pre-mRNA contacts while preserving U2AF65 and SF3a60 contacts. U2-containing complexes still formed without heparin but were destabilized by heparin challenge; the apparent assembly block depends on assay conditions. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
CWR22R IC50 0.6 nM Suppression of AR-V7 expression in human CWR22Rv1 cells expressing GFP measured after 3 days by FACS assay [PMID: 32551017]

Spliceostatin A Research Summary

This section summarizes 5 in vitro studies and 1 in vivo study of Spliceostatin A from 4 published references. In vitro models include HeLa nuclear extracts with model AdML pre-mRNA or its 3′ region; HeLa nuclear extracts and labeled AdML 3′ RNA.

Spliceostatin A In Vitro Studies

In U2OS cells, 100 nM spliceostatin A preserved early repair-factor recruitment after irradiation. Longer exposure induced DNA damage: after 48 h, the comet response and γH2AX induction were reversed by RNaseH1 expression, supporting an R-loop-associated effect. These results depend on exposure duration and endpoint. [2]

In a human RPE1 reporter model, 30 µM spliceostatin A treatment before serum starvation was associated with fewer primary cilia and more cycling cells than DMSO controls. This qualitative phenotype does not establish a ciliogenesis-specific molecular target. [3]

Splicing inhibition and heparin-sensitive U2 snRNP assembly

Biochemical assay · HeLa nuclear extracts with model AdML pre-mRNA or its 3′ region [1]

SSA inhibited splicing and accumulation of heparin-resistant A complexes. Without heparin, ATP-dependent U2-containing complexes still formed; this supports weakened assembly rather than universal prevention of initial U2 recruitment.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Accumulation of splicing intermediates/productsreported response Inhibition starting at 45 nM; essentially complete at 100 nM (authors’ narrative, not an IC50).[1]
U2 snRNP-containing complexesreported response Complexes formed without heparin but were sensitive to added heparin in the presence of SSA.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Splicing/assembly concentration series as labeled in Figs 1–2; 88.8 nM SSA in Fig 2B
Exposure duration
Splicing: 1 h; assembly: 15 min before heparin challenge
Method
Denaturing splicing gels and native complex assembly gels at 30°C
Vehicle
Methanol carrier control
Reported limits
No IC50, replicate count or statistical uncertainty assigned to gel-derived inhibition thresholds.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Compound-level cell-free mechanism; no supplier/lot inference.

Figs 1A–C, 2A–D; corresponding Results; Materials and methods: in vitro splicing assays and spliceosome assembly

Accumulation of splicing intermediates/products: AdML pre-mRNA splicing, denaturing PAGE — Results: Effects of SSA on spliceosome assembly; Fig 1A

U2 snRNP-containing complexes: Native gels with/without heparin; ATP and U2-inactivation controls — Fig 2A–D and caption; Results: SSA destabilizes U2 snRNP assembly

Biochemical assay · HeLa nuclear extracts and labeled AdML 3′ RNA [1]

SSA decreased SF3b155 cross-linking to pre-mRNA while U2AF65 and SF3a60 contacts were retained. U2 snRNA–pre-mRNA cross-linking was largely unaffected.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Protein–pre-mRNA cross-linking specificityreported response SF3b155 cross-linking decreased; U2AF65 and SF3a60 interactions were not affected.[1]
U2 snRNA–pre-mRNA cross-linkingreported response Largely unaffected by SSA treatment.[1]

Literature-Reported Treatment Conditions

Treatment concentration
88 nM for UV protein cross-linking; 53 or 267 nM in psoralen RNA cross-linking
Exposure duration
UV assay: 30 min incubation before irradiation
Method
UV cross-linking followed by immunoprecipitation; psoralen RNA–RNA cross-linking
Vehicle
Methanol
Reported limits
No direct binding affinity or stoichiometry measured here.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Interaction assay supports perturbation of SF3b-associated RNA contacts, not direct binding affinity.

Fig 3A–C and caption; Results: SSA leads to altered RNA–protein and RNA–RNA interactions; Materials and methods: UV cross-linking and immunoprecipitation

Protein–pre-mRNA cross-linking specificity: UV cross-linking/immunoprecipitation with methanol and mock/U2-inactivated extract controls — Fig 3A and caption; corresponding Results

U2 snRNA–pre-mRNA cross-linking: Psoralen cross-linking; RNA identity checked by RNase H analysis — Fig 3B–C and caption; corresponding Results

Preserved early repair-factor recruitment after irradiation

Cell-based study · Human U2OS osteosarcoma cells [2]

At 100 nM SSA, early irradiation-induced RAD51, BRCA1, RPA and pATM foci recruitment was retained relative to DMSO; isoginkgetin impaired these responses in the same comparison.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
RAD51, BRCA1, RPA and pATM foci after irradiationreported response No impairment reported with SSA under the early response conditions.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
24 h pretreatment, then 2 h after irradiation
Method
Immunofluorescence after 2 Gy irradiation; matched unirradiated controls
Vehicle
DMSO
Reported limits
No exact plotted percentages inferred. Figure caption reports two–three independent experiments collectively, without per-panel n assignment.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Condition-specific cellular limiting evidence; not general absence of DNA damage.

Fig 3B and caption; Results: Splicing inhibition reduces HR through attenuating transcription; cell culture/transfection methods

RAD51, BRCA1, RPA and pATM foci after irradiation: More than 400 cells per quantification; thresholds >12 foci for each named marker; figure-level s.e.m. from two–three independent experiments — Fig 3B and caption; corresponding Results

RNaseH1-sensitive DNA damage after prolonged SSA exposure

Cell-based study · Human U2OS cells with GFP-empty-vector or ectopic RNaseH1 expression [2]

SSA increased alkaline-comet DNA damage after 48 h. RNaseH1 expression reversed the comet response and rescued γH2AX induction, supporting an R-loop-associated component.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Alkaline-comet tail momentreported response SSA-induced increase reversed by RNaseH1 overexpression.[2]
γH2AX inductionreported response Induced after 48 h SSA; rescued by ectopic RNaseH1.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
48 h for SSA comet assay; western time course 0, 24, 48, 72 h
Method
Alkaline comet assay and immunoblotting; RNaseH1 rescue compared with empty vector
Vehicle
DMSO
Reported limits
Fig 6d y-axis is tail moment, despite caption describing tail length; use methods definition. Exact effect size not tabulated in the read material.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Cellular DNA-damage result with a rescue control; not an animal efficacy result.

Fig 6C–F and caption; Results: DNA damage caused by SNRPA1 depletion and SSA treatment; Comet assay and cell culture methods

Alkaline-comet tail moment: Tail moment = percent DNA in tail × tail length; methods: at least 200 comets per sample; caption n=200, three independent experiments, s.e.m. — Fig 6C–D and caption; Comet assay methods

γH2AX induction: Immunoblots with H2AX and β-actin controls — Fig 6E–F and caption; corresponding Results

Reduced primary-cilium formation after SSA treatment

Cell-based study · SEMG-hTERT-RPE1 cells expressing Smo-EGFP and mCherry-Geminin [3]

SSA-treated cells showed fewer cilia and more cycling cells than DMSO controls after serum starvation. Figure 4B provides representative images rather than a numerical dose–response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cilia and cycling-cell phenotype under serum starvationreported response Fewer ciliated cells and more cycling cells than DMSO controls (qualitative).[3]

Literature-Reported Treatment Conditions

Treatment concentration
30 µM
Exposure duration
24 h treatment before 48 h serum starvation; persistence of SSA during starvation is not explicit
Method
Fluorescence microscopy of Smo-EGFP-positive cilia and mCherry-Geminin-positive cycling cells
Vehicle
DMSO
Reported limits
Cell-treatment solvent percentage, washout/persistence during starvation, and panel-specific n not explicit in adopted text/caption.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Compound-level cell phenotype; paper-level catalog match does not validate current Adooq lots.

Fig 4A–B and caption; Results: Inhibition of mRNA splicing causes ciliary defects; Cell culture and cellular image analysis methods

Cilia and cycling-cell phenotype under serum starvation: Representative fluorescence images; no exact cell percentages extracted — Fig 4A–B; corresponding Results

Spliceostatin A In Vivo Studies

In a chicken chorioallantoic membrane assay, local 2 nM spliceostatin A supplementation reduced HeLa-induced microvessel formation. Exogenous VEGF rescued the response, and acetylated spliceostatin A was inactive. This local embryonic assay does not establish systemic antitumor efficacy. [4]

Suppression of HeLa-driven angiogenesis in chicken CAM

Animal study · Growing chicken chorioallantoic membrane with HeLa-containing gelatin sponge implants [4]

Local SSA supplementation reduced HeLa-induced microvessel formation. Exogenous VEGF restored vessel formation, while acetylated SSA lacked the inhibitory activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
HeLa-induced microvessel formationreported response Approximately 50% of control after SSA (authors’ narrative); near medium-alone level.[4]
VEGF rescue and inactive acetylated-SSA controlreported response 100 ng/mL exogenous VEGF restored microvessel formation; Ac-SSA did not inhibit angiogenesis.[4]

Conditions shared by the study groups

Route
Local gelatin sponge application to CAM
Frequency
Single sponge implantation
Treatment course
Embryonic day 8 to day 12
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
SSA
2 nM in HeLa-containing sponge suspension
HeLa-only and medium-alone sponge groupsReduced microvessel formation, approximately 50% of HeLa control.[4]
SSA plus exogenous VEGF
2 nM SSA plus 100 ng/mL VEGF
SSA alone and HeLa-only sponge groupsExogenous VEGF restored microvessel formation.[4]
SSA
Model: Chicken CAM with HeLa gelatin sponge implant
Reported limits: CAM solvent and total delivered drug mass not specified in adopted CAM description.
SSA plus exogenous VEGF
Model: Chicken CAM with HeLa gelatin sponge implant
Reported limits: CAM solvent and total delivered drug mass not specified in adopted CAM description.
Methods and source locations

Compound reported in the paper: Spliceostatin A; Compound label in the paper: SSA

Local embryonic angiogenesis assay; not systemic tumor regression or clinical efficacy.

Figs 4A–B and 5A–B with captions; CAM methods; Results: SSA inhibits in vivo tumor angiogenesis; Fig 1 material structures

HeLa-induced microvessel formation: Defined counting region; caption average ±SD, n=6–7; no exact bar-derived vessel counts — Fig 4A–B and caption; corresponding Results

VEGF rescue and inactive acetylated-SSA control: Matched CAM sponge assay; caption average ±SD, n=6–7 — Fig 5A–B and caption; CAM methods

SSA · Figs 4–5 and captions; CAM methods

SSA plus exogenous VEGF · Figs 4–5 and captions; CAM methods

Specifications

Manufacturer Adooq Bioscience
CAS Number 391611-36-2
Formula C28H43NO8
Molecular Weight 521.65
SMILES
C[C@H]1C[C@H]([C@H](O[C@H]1C/C=C(\C)/C=C/[C@@H]2[C@H]([C@@]3(C[C@@](O2)(C)OC)CO3)O)C)NC(=O)/C=C/[C@H](C)OC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Spliceostatin A Research References

  1. [1] Corrionero A, Miñana B, Valcárcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A Genes & development (2011). PMID: 21363963 DOI: 10.1101/gad.2014311 Source material
  2. [2] Tanikawa M, Sanjiv K, Helleday T, et al. The spliceosome U2 snRNP factors promote genome stability through distinct mechanisms; transcription of repair factors and R-loop processing Oncogenesis (2016). PMID: 27991914 DOI: 10.1038/oncsis.2016.70 Source material
  3. [3] Kim JH, Lee JE. Mitotic control by mRNA splicing regulators ensures primary cilia formation Animal cells and systems (2017). PMID: 30460047 DOI: 10.1080/19768354.2016.1261738 Source material
  4. [4] Furumai R, Uchida K, Komi Y, et al. Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF Cancer science (2010). PMID: 20726856 DOI: 10.1111/j.1349-7006.2010.01686.x Source material

Publications

8 publications citing this product

  1. Arfaoui A, .et al. , EMBO Mol Med, 2019, Oct;11(10):e9930 PMID: 31476112
  2. KE Mengwasser, .et al. , ‎Mol Cell, 2019, S1097-2765(18)31062-1 PMID: 30686591
  3. Sahar AlShareef, .et al. , BMC Genomics, 2017, 18: 260 PMID: 28347276
  4. Ling Y, .et al. , Plant J, 2017, Jan;89(2):291-309 PMID: 27664942
  5. Matthew J. Hangauer, .et al. , Nature, 2017, Nov 9; 551(7679): 247-250 PMID: 29088702
  6. Ji Hyun Kim, .et al. , Animal Cells and Systems, 2017, 21:1, 17-22 PMID: 30460047
  7. M Tanikawa, .et al. , Oncogenesis, 2016, Dec; 5(12): e280 PMID: 27991914
  8. Ji Hyun Kim, .et al. , Biochim Biophys Acta, 2016, Jun; 1863(6 Pt A): 1307-1318 PMID: 27033521

Added to your cart

View Cart Checkout
Loading...